Monashee Investment Management LLC An2 Therapeutics, Inc. Transaction History

Monashee Investment Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$13.92 - $21.0 $911,732 - $1.38 Million	-65,498 Reduced 65.83%	33,997 $696,000
Q3 2023 Nov 13, 2023	SELL	$7.58 - $16.08 $625,350 - $1.33 Million	-82,500 Reduced 45.33%	99,495 $1.6 Million
Q2 2023 Aug 10, 2023	SELL	$5.06 - $9.91 $331,288 - $648,827	-65,472 Reduced 26.46%	181,995 $1.55 Million
Q1 2023 May 05, 2023	SELL	$7.94 - $15.6 $1.61 Million - $3.16 Million	-202,533 Reduced 45.01%	247,467 $2.44 Million
Q4 2022 Feb 09, 2023	BUY	$8.51 - $16.78 $1.84 Million - $3.64 Million	216,670 Added 92.86%	450,000 $4.29 Million

Q2 2022 Aug 12, 2022	SELL	$7.7 - $18.82 $1.54 Million - $3.76 Million	-200,000 Reduced 46.15%	233,330 $1.81 Million
Q1 2022 May 12, 2022	BUY	$15.0 - $15.4 $6.5 Million - $6.67 Million	433,330 New	433,330 $6.53 Million

13.2M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $40.7M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Monashee Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Monashee Investment Management LLC with notifications on news.